Group 1 - Adverum Biotechnologies is a clinical-stage company focused on gene therapy for prevalent ocular diseases, aiming to establish a new standard of care to restore vision and prevent blindness [2] - The company is developing a novel gene therapy candidate, ixoberogene soroparvovec (Ixo-vec), intended as a one-time intravitreal injection for patients with neovascular or wet age-related macular degeneration [2] - Adverum's proprietary intravitreal platform is designed to provide durable, single-administration therapies, reducing the need for frequent ocular injections [2] Group 2 - Adverum will present at several upcoming investor conferences, including the 2024 RBC Global Healthcare Conference on May 14, 2024, the BofA Securities 2024 Health Care Conference on May 16, 2024, and the H.C. Wainwright 2nd Annual BioConnect Investor Conference on May 20, 2024 [1] - The company will provide on-demand webcasts of the panel discussions, accessible on its website, with replays available for at least 30 days following the presentations [1]

Company Performance - Adverum Biotechnologies (ADVM) has returned 50.6% year-to-date, significantly outperforming the Medical sector's average return of 0.3% [2] - The Zacks Consensus Estimate for ADVM's full-year earnings has increased by 40.7% over the past quarter, indicating stronger analyst sentiment and an improving earnings outlook [2] - Adverum Biotechnologies holds a Zacks Rank of 2 (Buy), suggesting a favorable investment outlook [1][2] Industry Context - Adverum Biotechnologies is part of the Medical - Biomedical and Genetics industry, which consists of 506 stocks and currently ranks 77 in the Zacks Industry Rank [3] - The average performance of stocks in the Medical - Biomedical and Genetics industry has declined by 8.8% this year, highlighting Adverum's superior performance [3] - In comparison, Aurora Cannabis Inc., which operates in the Medical - Products industry ranked 149, has a year-to-date return of 31.9% and a consensus EPS estimate increase of 46.7% over the past three months [2][3]

For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Has Adverum Biotechnologies (ADVM) been one of those stocks this year? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.Adverum Biotechnologies is one of 1054 individual stocks in the Medical sector. Collectively, these companies sit at #4 in the Zacks Sector Rank. The Zacks Sector Rank inc ...

One stock that might be an intriguing choice for investors right now is Adverum Biotechnologies, Inc. (ADVM) . This is because this security in the Medical - Biomedical and Genetics space is seeing solid earnings estimate revision activity, and is in great company from a Zacks Industry Rank perspective.This is important because, often times, a rising tide will lift all boats in an industry, as there can be broad trends taking place in a segment that are boosting securities across the board. This is arguably ...

A downtrend has been apparent in Adverum Biotechnologies (ADVM) lately with too much selling pressure. The stock has declined 28.7% over the past four weeks. However, given the fact that it is now in oversold territory and Wall Street analysts are majorly in agreement about the company's ability to report better earnings than they predicted earlier, the stock could be due for a turnaround.Here is How to Spot Oversold StocksWe use Relative Strength Index (RSI), one of the most commonly used technical indicat ...

For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Has Adverum Biotechnologies (ADVM) been one of those stocks this year? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.Adverum Biotechnologies is a member of the Medical sector. This group includes 1063 individual stocks and currently holds a Zacks Sector Rank of #4. The Zacks Sector Rank ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 _______________________________________________________________________________ FORM 10-K _______________________________________________________________________________ ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission Fi ...

Exhibit 99.1 Adverum Biotechnologies Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Pipeline Highlights and Corporate Updates - Preliminary LUNA data presented at the Annual Meeting of the Macula Society support potential best-in-class clinical activity and an encouraging safety profile in patients with wet AMD - - Completed $127.5 million private placement financing with new and existing institutional investors - - Cash runway expected into late 2025 - - 1-for-10 reverse stock spl ...

- Preliminary LUNA data presented at the Annual Meeting of the Macula Society support potential best-in-class clinical activity and an encouraging safety profile in patients with wet AMD - - Completed $127.5 million private placement financing with new and existing institutional investors - - Cash runway expected into late 2025 – - 1-for-10 reverse stock split to be effective March 21, 2024 - REDWOOD CITY, Calif., March 18, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (NASDAQ:ADVM), a clinical-st ...

There are plenty of penny stocks ready to pop. However, we have to remember that penny stocks are extremely risky, and can be costly in the end. So, one, never risk more than you can afford to lose on any penny stock. That’s even if you believe it’s a “sure thing.”Two, don’t just buy any penny stock out there. Make sure you do your due diligence. Three, take some advice from the SEC. “Penny stocks may trade infrequently — which means that it may be difficult to sell penny stock shares once you have them. Be ...